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South Africa’s overcrowded prisons 
are massive TB breeding grounds but 
there is ‘little political will’ to prioritise 
interventions which a joint university 
study in the Western Cape shows could 
reduce transmission by up to 94%. 
Simply implementing existing maximum 
cell occupancy regulations would reduce 
TB transmission by 30%, while active case 
finding, ventilation and reduced time 
in cells would do the rest, researchers 
at the universities of Cape Town and 
Stellenbosch claim.1 The study was cited 
by four internationally respected health-
linked activist organisations in a joint 
declaration on the eve of the third national 
bi-annual TB conference in Durban (12 - 
15 June). 
The Treatment Action Campaign, 
Section 27 (incorporating the AIDS Law 
Project), Médecins sans Frontières (MSF) 
and Oxfam (the international poverty relief 
confederation) said the university study 
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exposed a 90% probability of TB transmission 
per patient per year in Pollsmoor, a large 
prison in Tokai in the Cape Peninsula. 
Overcrowding was a major infection driver, 
with prisoners commonly held in mass cells 
in extremely close proximity for up to 23 
hours a day. Besides the obvious measures, 
the departments of correctional services and 
health should ensure that prisoners who 
were TB-positive were diagnosed earlier and 
received proper treatment to reduce mortality. 
Pollsmoor mirrors disease conditions in 
scores of other South African prisons.
South Africa has the fourth highest global 
incarceration rate, with more than 165 
000 prisoners in 237 operational prisons. 
There is a rapid turnover of awaiting-trial 
prisoners with 79% being incarcerated for 
periods of less than 12 months. The number 
of individuals passing through the prison 
system annually therefore exceeds 368 000.1 
A 2006 Judicial Inspectorate of Prisons report 
showed prisoner mortality in the country 
rose from 1.65 deaths/1 000 prisoners in 
1995 to 9.2 deaths/1 000 prisoners in 2005, a 
5-fold increase.2
Decentralise drug-
resistant TB care – and 
fast
If the country’s leading cause of death was 
to be reduced, it was ‘crucial’ that there 
be a general expansion of TB diagnosis 
and access to existing and improved 
treatment for TB and multi-drug-resistant 
TB (MDRTB). Services could no longer be 
limited to certain areas and facilities while 
better diagnostic tools and medicines and 
access to them were ‘vital’, the organisations 
said. Five crucial interventions were needed: 
diagnosing all people living with TB and 
drug-resistant (DR) TB; ensuring access to 
the best available medicines and regimens; 
improving the affordability of medicines; 
decentralising DR TB care; and reducing 
prison crowding and implementing active 
case finding and infection control. Calling 
for decentralised care to be rolled out 
nationally via the training of nurses to 
manage treatment and community health 
workers to support ongoing care, the group 
acknowledged the government’s policy shift 
to decentralisation but said the handful of 
current sites was simply not enough.
‘Nearly half of patients diagnosed with 
DR TB in South Africa are not initiated onto 
treatment and with only 2 500 beds for DR TB 
patients, centralised care is no longer possible 
or cost-effective,’ they said. One (unnamed) 
decentralised pilot site in KwaZulu-Natal 
had improved cure rates by 66.7% (versus 
the last recorded national DR TB treatment 
success rate of 48% in 2008). At Tugela 
Ferry District Hospital (where extensive 
MDRTB was first uncovered by its Principal 
Medical Officer, Dr Tony Moll 6 years ago), 
active case finding, decentralised care and 
infection control had decreased the rate of 
new MDR infections by half. (Ironically, the 
international publicity generated by Moll’s 
initial pragmatic sleuthing has generated 
funding and equipment for his hospital that 
is the envy of its peers.)
Hard bargaining/
creativity needed on 
medicine prices
The activists said that while the Department 
of Health had reduced the prices of several TB 
medicines during its last tender, the country 
continued to pay higher prices for many 
medicines than elsewhere internationally. 
Linezolid, for example, was unaffordable and 
should be available at lower costs. Pfizer charged 
R8 460 per patient per month (for linezolid) in 
the public sector and more than double this 
for NGOs such as MSF. Suggested solutions 
included importing lower-cost medicines 
from overseas or pooling procurement with 
other high TB burden countries. Funders and 
developers of new medicines in the pipeline 
should ensure that, once registered, they were 
made ‘widely available at low costs’.
The group lauded the introduction of the 
GeneXpert diagnostic tool by Cepheid (able 
to detect TB in many patients who currently 
test false-negative using smear microscopy 
plus detect rifampicin resistance), but 
criticised the cost of the machines and 
cartridges, saying a cost reduction would 
allow critically needed expanded use in all 
developing countries. More research was 
needed to discover cheap, laboratory-free, 
point-of-care diagnostics. Linezolid offered 
hope for patients failing on DR TB but was 
not yet widely available. The compassionate 
use of bedaquiline (promising results in 
Phase II trials) for patients who had no 
other treatment options provided a potential 
chance of cure and was already conditionally 
available in several countries. The group 
called for the Department of Health and 
the Medicines Control Council (MCC) to 
facilitate access to important new medicines 
in the pipeline for patients in dire need. 
Once these medicines received pre-approval 
from the Food and Drug Administration 
(FDA), they should be fast-tracked by the 
MCC. The group said funding for research 
into new medicines to shorten and simplify 
regimens and reduce side-effects (hearing 
loss, paranoia, depression and kidney 
failure) was critically needed. (TB regimens 
usually take 6 months to complete and DR 
TB regimens up to 2 years). 
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At Tugela Ferry District 
Hospital (where extensive 
MDRTB was first uncovered by 
its Principal Medical Officer, Dr 
Tony Moll 6 years ago), active 
case finding, decentralised 
care and infection control 
had decreased the rate of 
new MDR infections by half. 
(Ironically, the international 
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initial pragmatic sleuthing 
has generated funding and 
equipment for his hospital that 
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